ATE247460T1 - Kolloidale suspension von submikronischen teilchen als vektoren von aktiven prinzipien sowie deren herstellung - Google Patents

Kolloidale suspension von submikronischen teilchen als vektoren von aktiven prinzipien sowie deren herstellung

Info

Publication number
ATE247460T1
ATE247460T1 AT00968011T AT00968011T ATE247460T1 AT E247460 T1 ATE247460 T1 AT E247460T1 AT 00968011 T AT00968011 T AT 00968011T AT 00968011 T AT00968011 T AT 00968011T AT E247460 T1 ATE247460 T1 AT E247460T1
Authority
AT
Austria
Prior art keywords
suspension
insulin
active principles
colloidal suspension
vectors
Prior art date
Application number
AT00968011T
Other languages
English (en)
Inventor
Franck Touraud
Nathan Bryson
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Application granted granted Critical
Publication of ATE247460T1 publication Critical patent/ATE247460T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/044Suspensions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90Block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004Preparation of sols
    • B01J13/0021Preparation of sols containing a solid organic phase
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41Particular ingredients further characterized by their size
    • A61K2800/413Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Cosmetics (AREA)
AT00968011T 1999-11-23 2000-10-11 Kolloidale suspension von submikronischen teilchen als vektoren von aktiven prinzipien sowie deren herstellung ATE247460T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9914751A FR2801226B1 (fr) 1999-11-23 1999-11-23 Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
PCT/FR2000/002831 WO2001037809A1 (fr) 1999-11-23 2000-10-11 Suspension colloidale de particules submicroniques de vectorisation de principes actifs et leur mode de preparation

Publications (1)

Publication Number Publication Date
ATE247460T1 true ATE247460T1 (de) 2003-09-15

Family

ID=9552460

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968011T ATE247460T1 (de) 1999-11-23 2000-10-11 Kolloidale suspension von submikronischen teilchen als vektoren von aktiven prinzipien sowie deren herstellung

Country Status (19)

Country Link
US (2) US7226618B1 (de)
EP (1) EP1239836B1 (de)
JP (1) JP5095896B2 (de)
KR (1) KR100583929B1 (de)
CN (2) CN1823744A (de)
AT (1) ATE247460T1 (de)
AU (1) AU781539B2 (de)
BR (1) BR0015690A (de)
CA (1) CA2391986A1 (de)
DE (1) DE60004704T2 (de)
DK (1) DK1239836T3 (de)
ES (1) ES2206311T3 (de)
FR (1) FR2801226B1 (de)
HK (1) HK1052642A1 (de)
MX (1) MXPA02005191A (de)
NZ (1) NZ518875A (de)
PT (1) PT1239836E (de)
WO (1) WO2001037809A1 (de)
ZA (1) ZA200203618B (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814952B1 (fr) 2000-10-06 2004-01-02 Flamel Tech Sa Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
WO2002077075A1 (fr) * 2001-03-22 2002-10-03 Rhodia Chimie Procede de fabrication de particules colloidales de forme controlee avec des copolymeres a blocs hydrosolubles comprenant un bloc hydrophobe et un bloc hydrophile
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
JP4091917B2 (ja) * 2002-03-20 2008-05-28 ローディア,インコーポレイテッド 両親媒性ジブロック共重合体及び疎水性化合物を含むベシクル
CA2480824A1 (fr) 2002-04-09 2003-10-16 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
AU2003294056A1 (en) * 2002-12-04 2004-07-29 Flamel Technologies Polyamino acids functionalized by at least one (oligo)amino acid group and therapeutic uses
FR2855521B1 (fr) 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
FR2860516B1 (fr) 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862536B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2862541B1 (fr) * 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
FR2862535B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
FR2873040B1 (fr) * 2004-07-19 2007-11-30 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
FR2873703B1 (fr) 2004-07-30 2006-12-08 Flamel Technologies Sa Polyaminoacides branches, fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
JP4929567B2 (ja) * 2004-08-05 2012-05-09 コニカミノルタエムジー株式会社 ポリマーミセル含有製剤の製造方法
FR2881140B1 (fr) * 2005-01-27 2007-04-06 Flamel Technologies Sa Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
JP2006321763A (ja) * 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk 生体適合性ナノ粒子及びその製造方法
FR2892725B1 (fr) 2005-10-31 2011-03-04 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des derives de l'histidine et des groupements hydrophobes et leurs applications notamment therapeutiques
FR2896164B1 (fr) * 2006-01-18 2008-07-04 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
FR2902007B1 (fr) * 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
FR2915748B1 (fr) 2007-05-03 2012-10-19 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des groupes cationiques et des groupements hydrophobes et leurs applications, notamment therapeutiques
FR2915684B1 (fr) 2007-05-03 2011-01-14 Flamel Tech Sa Particules a base de polyelectrolytes et de principe actif a liberation modifiee et formulations pharmaceutiques contenant ces particules
FR2915683B1 (fr) 2007-05-03 2009-08-07 Flamel Technologies Sa Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
FR2954325B1 (fr) 2009-12-23 2012-02-03 Flamel Tech Sa Polymere amphiphile fonctionnalise par la methionine
US20110150837A1 (en) * 2009-12-23 2011-06-23 Flamel Technologies Amphiphilic polymer functionalized by methionine
FR2968993B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Nanoparticules comportant au moins un actif et au moins deux polyelectrolytes
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
FR2975301B1 (fr) 2011-05-20 2013-05-24 Flamel Tech Sa Composition comprenant un interferon alpha
WO2012159945A1 (en) 2011-05-20 2012-11-29 Ares Trading S.A. Ifn-beta compositions, preparation methods and uses thereof
KR101810055B1 (ko) 2011-08-10 2017-12-18 아도시아 하나 이상의 유형의 기저 인슐린의 주사액
ITMI20111866A1 (it) 2011-10-13 2013-04-14 Bio Ker S R L Polietilenglicoli modificati e loro complessi supramolecolari con macromolecole biologicamente attive
CN103930096B (zh) * 2011-10-31 2017-05-31 Xeris药物公司 用于治疗糖尿病的制剂
US9198971B2 (en) 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
WO2015064591A1 (ja) * 2013-10-28 2015-05-07 テルモ株式会社 タンパク質水性懸濁剤
CN107735406A (zh) * 2015-04-09 2018-02-23 丝芭博株式会社 极性溶剂溶液及其制造方法
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2017211917A1 (fr) 2016-06-07 2017-12-14 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
WO2018122278A1 (fr) 2016-12-27 2018-07-05 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110625A1 (fr) 2017-12-06 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
MX2020005915A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende glucagón humano y un copoliaminoácido.
US10987426B2 (en) 2017-12-07 2021-04-27 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
FR3083087A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
US20190275108A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
TWI813604B (zh) 2017-12-07 2023-09-01 法商阿道洽公司 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的可注射ph7溶液
FR3083086A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
US11129877B2 (en) 2017-12-07 2021-09-28 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
EP3723728A1 (de) 2017-12-07 2020-10-21 Adocia Injektionslösung mit einem ph-wert von 7 mit mindestens einem basalinsulin mit einem pi zwischen 5,8 und 8,5 und einer copolyaminosäure mit carboxylatladungen und hydrophoben radikalen
CN111670042A (zh) 2017-12-07 2020-09-15 阿道恰公司 包含人胰高血糖素和共聚氨基酸的可注射水溶液形式的组合物
MX2020005913A (es) 2017-12-07 2020-10-19 Adocia Solución inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoácido con cargas de carboxilato y radicales hidrofóbicos.
EP3740195A1 (de) 2017-12-07 2020-11-25 Adocia Zusammensetzungen in form einer injizierbaren wässrigen lösung mit amylin, einem amylin-rezeptor-agonist oder einem amylin-analogon und einer copolyaminosäure
WO2019110838A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3067247A1 (fr) 2018-06-07 2018-12-14 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
FR3084586B1 (fr) 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
FR3084584B1 (fr) 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3084585B1 (fr) 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
WO2020115334A1 (fr) 2018-12-07 2020-06-11 Adocia Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
WO2020245470A1 (fr) 2019-06-07 2020-12-10 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN116211929A (zh) * 2023-01-31 2023-06-06 福建益昕葆生物制药有限公司 一种用于防治团头鲂养殖中细菌性败血症的药物组合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
AU634606B2 (en) 1989-11-06 1993-02-25 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5286495A (en) 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
FR2708932B1 (fr) 1993-08-10 1995-11-10 Flamel Tech Sa Procédé de préparation de polyaminoacides.
JPH0881501A (ja) * 1994-03-22 1996-03-26 Agawamura 酸性多糖
JP2690276B2 (ja) 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
FR2746035B1 (fr) * 1996-03-15 1998-06-12 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
FR2814952B1 (fr) * 2000-10-06 2004-01-02 Flamel Tech Sa Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation

Also Published As

Publication number Publication date
CA2391986A1 (fr) 2001-05-31
NZ518875A (en) 2006-01-27
EP1239836B1 (de) 2003-08-20
AU7798600A (en) 2001-06-04
AU781539B2 (en) 2005-05-26
CN1399541A (zh) 2003-02-26
ZA200203618B (en) 2003-07-30
DE60004704T2 (de) 2004-07-08
US7226618B1 (en) 2007-06-05
DE60004704D1 (de) 2003-09-25
US20070248686A1 (en) 2007-10-25
ES2206311T3 (es) 2004-05-16
FR2801226A1 (fr) 2001-05-25
KR20020067040A (ko) 2002-08-21
JP5095896B2 (ja) 2012-12-12
CN1823744A (zh) 2006-08-30
KR100583929B1 (ko) 2006-05-26
JP2003514844A (ja) 2003-04-22
FR2801226B1 (fr) 2002-01-25
DK1239836T3 (da) 2003-11-24
HK1052642A1 (zh) 2003-09-26
WO2001037809A1 (fr) 2001-05-31
EP1239836A1 (de) 2002-09-18
BR0015690A (pt) 2002-07-09
MXPA02005191A (es) 2003-09-22
PT1239836E (pt) 2004-01-30

Similar Documents

Publication Publication Date Title
ATE247460T1 (de) Kolloidale suspension von submikronischen teilchen als vektoren von aktiven prinzipien sowie deren herstellung
Ma et al. Phenylboronic acid-based glucose-responsive polymeric nanoparticles: synthesis and applications in drug delivery
Chauvierre et al. Novel polysaccharide-decorated poly (isobutyl cyanoacrylate) nanoparticles
DE69402310D1 (de) Verwendung einer transacylierungsreaktion, zwischen einem veresterten polysaccharid und einem polyamin, um im wässerigem medium wenigstens an der oberflaeche aus gelierten partikeln eine membran zu formen,so hergestellte partikel,diese enthaltende zusammensetzungen und verfahren
BR0208605A (pt) Suspensão coloidal de nanopartìculas à base de copolìmero anfìfilo, para a vetorização de princìpios ativos
AU1288201A (en) Composite nanospheres and their conjugates with biomolecules
CA2016505A1 (en) Water soluble high molecular polymerized drug preparation
Baran et al. Poly (hydroxybutyrate-co-hydroxyvalerate) nanocapsules as enzyme carriers for cancer therapy: an in vitro study
NZ220323A (en) 3-dimensional network of microspheres containing biologically active macromolecular agents
Seo et al. pH-dependent hemolysis of biocompatible imidazole-grafted polyaspartamide derivatives
HK1071390A1 (en) Ph responsive biodegradable polylactic acid derivatives forming polymeric micelles and uses thereof for poorly water soluble drug delivery
BR0114513A (pt) Suspensão coloidal, sólida pulverulento, processo de preparação do sólido pulverulento, processo de preparação da suspensão, produtos intermediários do processo e especialidade farmacêutica, nutricional, fitossanitária ou cosmética
Liu et al. Synthesis of chitosan-based nanohydrogels for loading and release of 5-fluorouracil
AU2015377981B2 (en) Reductively degradable polyzwitterionic nano-micelles and preparation method thereof
CN104418971A (zh) 葡萄糖氧化酶介导自由基引发体系及其制备水凝胶的方法
CN105381472A (zh) 月见草素b-酪蛋白磷酸肽-壳聚糖纳米粒及制备方法与应用
DE3871176D1 (de) Mikroenkapsulierung von biologisch aktivem material.
Hafızosmanoğlu et al. Fabrication of Oleic Acid Grafted Starch‐based Hybrid Carriers for l‐Asparaginase Encapsulation
Yin et al. Preparation and characterization of sodium alginate/chitosan composite nanoparticles loaded with chondroitin sulfate
Onal et al. Synthesis and characterization of chitosan-based pH-sensitive biofilm: An experimental design approach for release of vitamin B12
Talaei et al. Core shell methyl methacrylate chitosan nanoparticles: In vitro mucoadhesion and complement activation
Salehi et al. Thermosensitive nanoparticles prepared from poly (N‐isopropylacrylamide‐acrylamide‐vinilpyrrolidone) and its blend with poly (lactide‐co‐glycolide) for efficient drug delivery system
López et al. Cellular evaluation of insulin transmucosal delivery
Lin et al. Dual‐responsive crosslinked micelles of a multifunctional graft copolymer for drug delivery applications
Basu et al. Synthesis and characterization of ramipril embedded nanospheres of biodegradable poly-d, l-lactide-co-glycolide and their kinetic release study

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1239836

Country of ref document: EP

REN Ceased due to non-payment of the annual fee